Axsome Therapeutics Q3 Results: Analysts Predict 72% Revenue Growth and $0.70 EPS for 2026

Axsome Therapeutics reported Q3 results with revenues of $171m, slightly ahead of analyst estimates, but statutory losses were 7.3% larger at $0.94 per share. Analysts forecast revenues of $967.1m in 2026, a 72% improvement from the last 12 months, and a statutory profit of $0.70 per share. The consensus price target is $182, with a range of individual analyst targets from $205 to $148 per share.